RESUMEN
PURPOSE: L-Ascorbic acid (vitamin C) is an essential water-soluble vitamin that plays an important role in various physiological functions, including immune health. The stability of vitamin C in the gastrointestinal tract its bioavailability is limited. This study aimed to investigate if a liposomal form of vitamin C can increase absorption compared to standard vitamin C. METHODS: In a randomized, double-blind, placebo-controlled, crossover fashion, 19 males and 8 females (n = 27; 36.0 ± 5.1 years, 165.0 ± 6.9 cm, 70.6 ± 7.1 kg) ingested a single-dose of placebo (PLA), 500 mg vitamin C (VIT C), and 500 mg liposomal vitamin C (LV-VIT C, LipoVantage®, Specnova, LLC, Tyson Corner, VA, USA). Venous blood samples were collected 0, 0.5-, 1-, 1.5-, 2-, 3-, 4-, 6-, 8-, 12-, and 24-hours after ingestion and were analyzed for plasma and leukocyte vitamin C concentration. RESULTS: VIT C and LV-VIT C demonstrated significantly greater Cmax and AUC0 - 24 in plasma and in leukocytes compared to placebo (p < 0.001). Additionally, LV-VIT C had significantly higher Cmax (plasma + 27%, leukocytes + 20%, p < 0.001) and AUC0 - 24 (plasma + 21%, leukocytes + 8%, p < 0.001) values as compared to VIT C. CONCLUSION: Liposomal formulation of vitamin C increases absorption into plasma and leukocytes. TRIAL REGISTRATION: Clinical Trials Registry - India (CTRI/2023/04/051789).
Asunto(s)
Ácido Ascórbico , Estudios Cruzados , Leucocitos , Liposomas , Humanos , Ácido Ascórbico/administración & dosificación , Ácido Ascórbico/farmacología , Ácido Ascórbico/farmacocinética , Método Doble Ciego , Masculino , Femenino , Adulto , Leucocitos/efectos de los fármacos , Leucocitos/metabolismo , Disponibilidad Biológica , Suplementos Dietéticos , Absorción Intestinal/efectos de los fármacos , Sistemas de Liberación de Medicamentos/métodos , Persona de Mediana EdadRESUMEN
This study aimed to synthesize a nano-structure between selenium, Vit. C, and Vit. E (Vit-E/C@SeNPs) as a promising protective and therapeutic agent for hepatocellular carcinoma. Vit-E/C@SeNPs were characterized using TEM and DLS and its zetapotential was measured to evaluate its stability. DPPH assay and SRB test were performed to estimate its antioxidant capacity and cytotoxicity, respectively. A radiosynthesis of 99mTc-Vit-E/C@SeNPs was done for further in-vivo pharmacokinetic studies on normal and solid tumor induced mice. Further, in-vivo studies were conducted to investigate Vit-E/C@SeNPs efficacy against hepatocellular damage in Wistar albino rats induced by diethylnitrosamine (DEN) / Carbon Tetra chloride (CCl4). The synthesis results showed spherical Vit-E/C@SeNPs with core size of 50 nm, radical scavenging activity (%RSC) of 75.9%, and IC50 of 27.9 µg/ml. The biochemical analysis results showed that the lower liver function biomarker values (ALT, AST, ALP, total bilirubin and GGT) has gone for the Vit-E/C@SeNPs prevention and treated group, which also showed significant depletion of liver tissue l-MDA, and obvious increase in GSH concentration and CAT activity and marked improvement in the histological feature of liver tissue. Additionally, a significant up-regulation of mRNA gene expression levels of inflammatory gene (TGFß1, NFκB, iNOS, PPAR-γ and TNFα) and Apoptotic gene (P53) were determined by using Quantitative real-time PCR (qPCR). The values down regulate and tend to normal in prevention and control group. All of these introduce Vit-E/C@SeNPs as a promising agent as protective and therapeutic agent against DEN/ CCl4-induced hepatocellular damage (Hepatocellular carcinoma).
Asunto(s)
Antioxidantes/farmacología , Ácido Ascórbico/farmacología , Hígado/efectos de los fármacos , Selenio/farmacología , Vitamina E/farmacología , Animales , Antioxidantes/administración & dosificación , Antioxidantes/farmacocinética , Ácido Ascórbico/administración & dosificación , Ácido Ascórbico/farmacocinética , Carcinoma Hepatocelular/tratamiento farmacológico , Línea Celular , Humanos , Hígado/metabolismo , Neoplasias Hepáticas/tratamiento farmacológico , Masculino , Nanopartículas/administración & dosificación , Nanopartículas/análisis , Ratas , Ratas Wistar , Selenio/administración & dosificación , Selenio/farmacocinética , Vitamina E/administración & dosificación , Vitamina E/farmacocinéticaRESUMEN
Chemotherapy and radiotherapy are the most frequent treatment for patients suffering from malignant progression of cancer. Even though new treatments are now being implemented, administration of these chemotherapeutic agents remains as the first line option in many tumor types. However, the secondary effects of these compounds represent one of the main reasons cancer patients lose life quality during disease progression. Recent data suggests that Ocoxin, a plant extract and natural compound based nutritional complement rich in antioxidants and anti-inflammatory mediators exerts a positive effect in patients receiving chemotherapy and radiotherapy. This mixture attenuates the chemotherapy and radiotherapy-related side effects such as radiation-induced skin burns and mucositis, chemotherapy-related diarrhea, hepatic toxicity and blood-infection. Moreover, it has been proven to be effective as anticancer agent in different tumor models both in vitro and in vivo, potentiating the cytotoxic effect of several chemotherapy compounds such as Lapatinib, Gemcitabine, Paclitaxel, Sorafenib and Irinotecan. The aim of this review is to put some light on the potential of this nutritional mixture as an anticancer agent and complement for the standard chemotherapy routine.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Ácido Ascórbico/administración & dosificación , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Ácido Fólico/administración & dosificación , Neoplasias/terapia , Ácido Pantoténico/administración & dosificación , Extractos Vegetales/administración & dosificación , Traumatismos por Radiación/prevención & control , Vitamina B 12/administración & dosificación , Vitamina B 6/administración & dosificación , Sulfato de Zinc/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Ácido Ascórbico/farmacocinética , Quimioradioterapia/efectos adversos , Quimioradioterapia/métodos , Ensayos Clínicos como Asunto , Resistencia a Antineoplásicos/efectos de los fármacos , Sinergismo Farmacológico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Ácido Fólico/farmacocinética , Humanos , Ácido Pantoténico/farmacocinética , Extractos Vegetales/farmacocinética , Traumatismos por Radiación/etiología , Tolerancia a Radiación/efectos de los fármacos , Resultado del Tratamiento , Vitamina B 12/farmacocinética , Vitamina B 6/farmacocinética , Sulfato de Zinc/farmacocinéticaRESUMEN
Tetrahexyldecyl Ascorbate (THDC) is an L-ascorbic acid precursor with improved stability and ability to penetrate the epidermis. The stability and transdermal penetration of THDC, however, may be compromised by the oxidant-rich environment of human skin. In this study, we show that THDC is a poor antioxidant that degrades rapidly when exposed to singlet oxygen. This degradation, however, was prevented by combination with acetyl zingerone (AZ) as a stabilizing antioxidant. As a standalone ingredient, THDC led to unexpected activation of type I interferon signaling, but this pro-inflammatory effect was blunted in the presence of AZ. Moreover, the combination of THDC and AZ increased expression of genes associated with phospholipid homeostasis and keratinocyte differentiation, along with repression of MMP1 and MMP7 expression, inhibition of MMP enzyme activity, and increased production of collagen proteins by dermal fibroblasts. Lastly, whereas THDC alone reduced viability of keratinocytes exposed to oxidative stress, this effect was completely abrogated by the addition of AZ to THDC. These results show that AZ is an effective antioxidant stabilizer of THDC and that combination of these products may improve ascorbic acid delivery. This provides a step towards reaching the full potential of ascorbate as an active ingredient in topical preparations.
Asunto(s)
Antioxidantes , Ácido Ascórbico , Colágeno/biosíntesis , Fibroblastos/metabolismo , Guayacol/análogos & derivados , Estrés Oxidativo/efectos de los fármacos , Antioxidantes/farmacocinética , Antioxidantes/farmacología , Ácido Ascórbico/farmacocinética , Ácido Ascórbico/farmacología , Línea Celular , Guayacol/farmacocinética , Guayacol/farmacología , HumanosRESUMEN
OBJECTIVES: The safety assessment of personal care products often entails determining dermal absorption of their ingredients. Such experiments are typically performed in human or animal skin in vitro; however, ethical and safety considerations are associated with obtaining these tissues. Several human skin equivalent models (HSEs) have been developed as alternatives to human tissue. The barrier function of such models however, is normally less developed than human skin. Here, we examine the permeability of the HSE LabSkinTM to a model compound, 3-O-ethyl-l-ascorbic acid (EA) compared with human skin. METHODS: Skin uptake and permeation of EA was investigated in vitro using heat-separated human epidermis and LabSkinTM . Finite dose (5 µL cm-2 ) Franz-diffusion studies were conducted using 2 % (w/w) EA in a ternary solvent mixture comprising propylene glycol (PG), propylene glycol monolaurate (PGML), and isopropyl myristate (IPM). These excipients are commonly used in cosmetic products and they have been reported to promote permeation of EA in a different model, namely porcine skin. RESULTS: Permeation of EA through LabSkinTM was evident from 2 h; however, EA permeation in human skin was not detected until 5 h. Similar amounts of EA permeated through the two membranes at time points 8, 10, 12 and 24 h (p > 0.05). The cumulative amounts of EA delivered through LabSkinTM at 24 h were 41.3 ± 2.0 µg cm-2 , corresponding to 55.1 ± 1.8 % of the applied dose. Similar amounts permeated across human skin, 49.4 ± 4.1 µg cm-2 , accounting for 58.0 ± 4.2 % of the dose applied (p > 0.05). CONCLUSION: The permeation of EA in LabSkinTM compared well with results for human epidermis in terms of the permeation profiles and the cumulative amounts of EA that permeated. The data suggest that the skin barrier of the two models was similar with regard to their overall permeability to the hydrophilic active EA. The findings are promising for the use of LabSkinTM as a surrogate for human skin in permeability testing. Future studies will focus on exploring the reproducibility and robustness of LabSkinTM for delivery of other actives that span a range of physicochemical properties.
OBJECTIFS: L'évaluation de la sécurité des produits de soins personnels implique souvent de déterminer l'absorption cutanée de leurs ingrédients. Ces expérimentations sont généralement réalisées in vitro sur la peau humaine ou animale ; cependant, des considérations éthiques et de sécurité sont associées à l'obtention de ces tissus. Plusieurs modèles équivalents de peau humaine (Human Skin Equivalent, HSE) ont été développés comme alternatives au tissu humain. La fonction barrière de ces modèles est cependant normalement moins développée que la peau humaine. Ici, nous examinons la perméabilité du HSE LabSkin™ à un composé modèle, l'acide 3-O-éthyl-l-ascorbique (EA) en le comparant à la peau humaine. MÉTHODES: L'absorption cutanée et la perméation de l'EA ont été étudiées in vitro à l'aide d'épiderme humain séparé par la chaleur et de LabSkin™. Des études de diffusion de Franz à dose limitée (5 µL cm-2 ) ont été réalisées en utilisant 2 % (p/p) d'EA dans un mélange de solvant ternaire contenant du propylène glycol (PG), du propylène glycol monolaurate (PGML) et du myristate d'isopropyle (IPM). Ces excipients sont fréquemment utilisés dans les produits cosmétiques et il a été rapporté qu'ils favorisent la perméation de l'EA dans un modèle différent, à savoir la peau porcine. RÉSULTATS: La perméation de l'EA par LabSkin™ était évidente dès 2 h ; cependant, la perméation de l'EA dans la peau humaine n'a pas été détectée avant 5 h. Des quantités similaires d'EA ont pénétré les deux membranes aux points temporels 8, 10, 12 et 24 h (p > 0,05). Les quantités cumulées d'EA délivrées par LabSkin™ à 24 h étaient de 41,3 ± 2,0 µg cm-2 , correspondant à 55,1 ± 1,8 % de la dose appliquée. Des quantités similaires ont pénétré la peau humaine, 49,4 ± 4,1 µg cm-2 , représentant 58,0 ± 4,2 % de la dose appliquée (p > 0,05). CONCLUSION: La perméation de l'EA dans LabSkin™ a bien soutenu la comparaison quant aux résultats concernant l'épiderme humain en termes de profils de perméation et de quantités cumulées d'EA qui ont pénétré. Les données suggèrent que la barrière cutanée des deux modèles était similaire en ce qui concerne leur perméabilité globale à l'EA hydrophile actif. Les résultats sont prometteurs pour l'utilisation de LabSkin™ en tant que substitut de la peau humaine dans les tests de perméabilité. Les études futures se concentreront sur l'exploration de la reproductibilité et de la robustesse de LabSkin™ pour la délivrance d'autres principes actifs qui couvrent un éventail de propriétés physicochimiques.
Asunto(s)
Ácido Ascórbico/análogos & derivados , Absorción Cutánea/efectos de los fármacos , Piel/efectos de los fármacos , Administración Cutánea , Ácido Ascórbico/administración & dosificación , Ácido Ascórbico/farmacocinética , Sistemas de Liberación de Medicamentos/métodos , Humanos , Permeabilidad , Piel/metabolismoRESUMEN
Antioxidants have gained marked attention owing to their ability to prevent the oxidation of biological components and to protect the body from reactive oxygen species, thereby maintaining human health. Thus, antioxidant-rich dietary supplements and natural foods can be effective against oxidative stress and can even act as chemopreventive agents. Therefore, a simple and rapid assay for evaluation of antioxidant capacity and assessment of their distribution profile in natural sources is vital. Herein, we report a rapid, innovative chemiluminescence (CL) platform for evaluation and visualization of antioxidant capacity. We found that intense and long-lasting CL was formed upon the redox reaction of quinones, e.g., menadione, with antioxidants, e.g., l-ascorbic acid, in the presence of luminol. The produced CL intensities were proportional to the antioxidants' concentrations with a detection limit of 0.18 µM for the model antioxidant, l-ascorbic acid. As the formed CL was long-lasting, it could be easily captured and detected with a charge-coupled device (CCD) camera. To evaluate the quantification ability of the CCD camera, we developed a smart and fast microplate-based assay based on photographing the generated CL with a cooled CCD camera. The photographed CL intensities were linearly proportional with the antioxidant concentrations, and then the method was applied for photographing multiple food sample extracts. Ultimately, we utilized our method for the distribution profiling of antioxidant capacity in food cut sections. Samples were dipped in luminol and then in quinone, followed by CCD camera photography, without the need for any pulverization/extraction procedure, giving precise antioxidant distribution information.
Asunto(s)
Antioxidantes/análisis , Ácido Ascórbico/análisis , Mediciones Luminiscentes , Antioxidantes/farmacocinética , Ácido Ascórbico/farmacocinética , Benzoquinonas/química , Humanos , Luminol/química , Estructura Molecular , Distribución TisularRESUMEN
Background: The efficacy of Vitamin C (L-ascorbic acid) supplementation can be assessed by uptake into the blood and retention in leukocytes. Vitafusion® Power C gummy is an alternative vitamin C source which may exhibit similar bioavailability to comparator caplets.Objective: The objective of this study was to evaluate the bioequivalence of vitamin C from a vitafusion® Power C gummy formulation and a comparator caplet in healthy adults.Methods: Thirty healthy men and women, 34.0 ± 11.4 years of age and Body Mass Index (BMI) 24.5 ± 3.6 kg/m2 completed the randomized examiner-blind, comparator controlled, cross-over trial with two sequences: gummy (1000 mg) to caplet (1000 mg) or caplet to gummy. Intake of foods fortified with Vitamin C was restricted 7 days prior to each dosing. Blood samples were collected pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 h post-dose for plasma and leukocytes; and urine was collected pre-dose and between 0-2, 2-4, 4-8, 8-12 and 12-24 h post-dose for L-ascorbic acid analysis.Results: Vitafusion® Power C gummy and comparator caplet demonstrated similar plasma absorption profiles as there were no significant differences in plasma L-ascorbic acid total Area Under the Curve (AUC)0-24h, and Tmax between gummy and caplet. The caplet did elicit a significantly higher Cmax than the gummy (p < 0.05), however, the difference was numerically small. Leukocyte L-ascorbic acid total AUC0-24h and Cmax were not significantly different between gummy and caplet, however Tmax of the gummy group was significantly longer (p = 0.012). Urinary L-ascorbic acid levels were also not significantly different between gummy and caplet. There were no serious adverse events and safety parameters remained within normal clinical range for both products.Conclusion: Vitafusion® Power C gummy exhibited similar Vitamin C absorption and bioavailability to a comparator caplet in healthy adults and were considered bioequivalent.
Asunto(s)
Ácido Ascórbico/farmacocinética , Composición de Medicamentos/métodos , Vitaminas/farmacocinética , Absorción Fisiológica , Administración Oral , Adulto , Área Bajo la Curva , Ácido Ascórbico/sangre , Ácido Ascórbico/orina , Disponibilidad Biológica , Estudios Cruzados , Femenino , Voluntarios Sanos , Humanos , Leucocitos/química , Masculino , Método Simple Ciego , Equivalencia Terapéutica , Vitaminas/sangre , Vitaminas/orinaRESUMEN
Recent interest in the role of ascorbate in crucial metabolic processes is driven by the growing number of medical reports that show beneficial effects of ascorbate supplementation for maintaining general well-being and recovery from a variety of medical conditions. The effect of ascorbate on the local body environment highly depends on its local concentration; at low concentrations it can cause the reduction of reactive oxygen and facilitate activities of enzymes, while at high concentrations it generates free radicals by reducing ferric ions. Ascorbate serving as an electron donor assists the iron-containing proteins and the iron transfer between various aqueous compartments. These functions require effective and adjustable mechanisms responsible for ascorbate biodistribution. In the paper we propose a new biophysical model of ascorbate redistribution between various aqueous body compartments. It combines recent experimental evidence regarding the ability of ascorbate to cross the lipid bilayer by unassisted diffusion, with active transport by well-characterized sodium vitamin C transporter (SVCT) membrane proteins. In the model, the intracellular concentration of ascorbate is maintained by the balance of two opposing fluxes: fast active and slow passive transport. The model provides a mechanistic understanding of ascorbate flux across the epidermal barrier in the gut as well as the role of astrocytes in ascorbate recycling in the brain. In addition, ascorbate passive diffusion across biological membranes, which depends on membrane electric potentials and pH gradients, provides the rationale for the correlation between ascorbate distribution and the transfer of iron ions inside a cell. The proposed approach provides, for the first time, a mechanistic account of processes leading to ascorbate physiological and cellular distribution, which helps to explain numerous experimental and clinical observations.
Asunto(s)
Ácido Ascórbico/metabolismo , Ácido Ascórbico/farmacocinética , Animales , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Homeostasis/efectos de los fármacos , Humanos , Concentración de Iones de Hidrógeno , Membrana Dobles de Lípidos , Modelos Biológicos , Transportadores de Sodio Acoplados a la Vitamina C/metabolismoRESUMEN
Vitamin C is the exogenous compound necessary for a variety of metabolic processes; therefore, the efficient delivery is critical for the maintenance of body homeostasis. Vitamin C pharmacokinetics and low quantities in processed foodstuff, necessitates its continuous supplementation. In the paper, we present the new liposomal formulation of vitamin C free of harmful organic solvents. The formulation was quantitatively characterized with respect to its chemically composition and nano-structuring. The vitamin C accessibility to cells from the formulation was evaluated using evidence derived from experiments performed on cell cultures. Finally, the enhanced bioavailability of vitamin C from the formulation was demonstrated in the medical experiment.
Asunto(s)
Ácido Ascórbico/administración & dosificación , Ácido Ascórbico/farmacocinética , Administración Oral , Ácido Ascórbico/química , Disponibilidad Biológica , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Relación Dosis-Respuesta a Droga , Composición de Medicamentos , Humanos , LiposomasRESUMEN
Although it is now well established that heart failure with preserved ejection fraction (HFpEF) is associated with marked inflammation and a prooxidant state that is accompanied by vascular dysfunction, whether acute antioxidant (AO) administration can effectively target these disease-related decrements has not been evaluated. Thus, the present study sought to evaluate the efficacy of an acute over-the-counter AO cocktail (600 mg α-lipoic acid, 1,000 mg vitamin C, and 600 IU vitamin E) to mitigate inflammation and oxidative stress, and subsequently improve nitric oxide (NO) bioavailability and vascular function, in patients with HFpEF. Flow-mediated dilation (FMD) and reactive hyperemia (RH) were evaluated to assess conduit vessel and microvascular function, respectively, 90 min after administration of either placebo (PL) or AO in 16 patients with HFpEF (73 ± 10 yr, EF 54-70%) using a double-blind, crossover design. Circulating biomarkers of inflammation (C-reactive protein, CRP), oxidative stress (malondialdehyde and protein carbonyl), free radical concentration (EPR spectroscopy), antioxidant capacity, ascorbate and NO bioavailability (plasma nitrate, [Formula: see text], and nitrite, [Formula: see text]) were also assessed. FMD improved following AO administration (PL: 3.49 ± 0.7%, AO: 5.83 ± 1.0%), whereas RH responses were similar between conditions (PL: 428 ± 51 mL, AO: 425 ± 51 mL). AO administration decreased CRP (PL: 4,429 ± 705 ng/mL, AO: 3,664 ± 520 ng/mL) and increased ascorbate (PL: 30.0 ± 2.9 µg/mL, AO: 45.1 ± 3.7 µg/mL) and [Formula: see text] (PL: 182 ± 21 nM, AO: 213 ± 24 nM) but did not affect other biomarkers. Together, these data suggest that acute AO administration can exert anti-inflammatory effects and improve conduit artery vasodilation, but not microvascular function, in patients with HFpEF.
Asunto(s)
Antioxidantes/farmacología , Ácido Ascórbico/farmacocinética , Insuficiencia Cardíaca/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Volumen Sistólico/efectos de los fármacos , Antioxidantes/administración & dosificación , Antioxidantes/metabolismo , Ácido Ascórbico/administración & dosificación , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/fisiopatología , Insuficiencia Cardíaca/fisiopatología , Humanos , Hiperemia/tratamiento farmacológico , Hiperemia/fisiopatología , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Volumen Sistólico/fisiología , Función Ventricular Izquierda/efectos de los fármacos , Función Ventricular Izquierda/fisiología , Vitamina E/metabolismoRESUMEN
The aim of this study was to design a nanocarrier system for inhalation delivery of rifampicin (RIF) in combination with ascorbic acid (ASC), namely constituted of sodium alginate coated with chitosan and Tween 80 (RIF/ASC NPs) as a platform for the treatment of pulmonary tuberculosis infection. A Box-Behnken experimental design and response surface methodology (RSM) were applied to elucidate and evaluate the effects of several factors on the nanoparticle properties. On the other hand, it was found that RIF/ASC NPs were less cytotoxic than the free RIF, showing a significantly improved activity against nine clinical strains of Mycobacterium tuberculosis (M. tb) in comparison with the free drug. RIF/ASC NPs had an average particle size of 324.0 ± 40.7 nm, a polydispersity index of 0.226 ± 0.030, and a zeta potential of - 28.52 ± 0.47 mV and the surface was hydrophilic. The addition of sucrose (1% w/v) to the nanosuspension resulted in the formation of a solid pellet easily redispersible after lyophilization. RIF/ASC NPs were found to be stable at different physiological pH values. In summary, findings of this work highlight the potential of the RIF/ASC NP-based formulation development herein to deliver RIF in combination with ASC through pulmonary route by exploring a non-invasive route of administration of this antibiotic, increasing the local drug concentrations in lung tissues, the primary infection site, as well as reducing the risk of systemic toxicity and hence improving the patient compliance.
Asunto(s)
Alginatos/administración & dosificación , Ácido Ascórbico/administración & dosificación , Quitosano/administración & dosificación , Mycobacterium tuberculosis/efectos de los fármacos , Nanopartículas/administración & dosificación , Rifampin/administración & dosificación , Alginatos/química , Alginatos/farmacocinética , Animales , Antibióticos Antituberculosos/administración & dosificación , Antibióticos Antituberculosos/química , Antibióticos Antituberculosos/farmacocinética , Ácido Ascórbico/química , Ácido Ascórbico/farmacocinética , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Quitosano/química , Quitosano/farmacocinética , Chlorocebus aethiops , Relación Dosis-Respuesta a Droga , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/química , Portadores de Fármacos/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Humanos , Mycobacterium tuberculosis/metabolismo , Nanopartículas/química , Nanopartículas/metabolismo , Tamaño de la Partícula , Rifampin/química , Rifampin/farmacocinética , Células VeroRESUMEN
Background and objectives: Ascorbic acid, alpha lipoic acid (ALA) and silymarin are well-known antioxidants that have hepatoprotective effects. This study aims to investigate the effects of these three compounds combined with attenuating drug-induced oxidative stress and cellular damage, taking acetaminophen (APAP)-induced toxicity in rats as a model both in vivo and in vitro. Materials and Methods: Freshly cultured primary rat hepatocytes were treated with ascorbic acid, ALA, silymarin and their combination, both with and without the addition of APAP to evaluate their in vitro impact on cell proliferation and mitochondrial activity. In vivo study was performed on rats supplemented with the test compounds or their combination for one week followed by two toxic doses of APAP. Results: Selected liver function tests and oxidative stress markers including superoxide dismutase (SOD), malondialdehyde (MDA) and oxidized glutathione (GSSG) were detected. The in vivo results showed that all three pretreatment compounds and their combination prevented elevation of SOD and GSSG serum levels indicating a diminished burden of oxidative stress. Moreover, ascorbic acid, ALA and silymarin in combination reduced serum levels of liver enzymes; however, silymarin markedly maintained levels of all parameters to normal ranges. Silymarin either alone or combined with ascorbic acid and ALA protected cultured rat hepatocytes and increased cellular metabolic activity. The subjected agents were capable of significantly inhibiting the presence of oxidative stress induced by APAP toxicity and the best result for protection was seen with the use of silymarin. Conclusions: The measured liver function tests may suggest an augmented hepatoprotection of the combination preparation than when compared individually.
Asunto(s)
Acetaminofén/efectos adversos , Ácido Ascórbico/farmacocinética , Factores Protectores , Silimarina/farmacocinética , Ácido Tióctico/farmacocinética , Acetaminofén/envenenamiento , Animales , Ácido Ascórbico/uso terapéutico , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/complicaciones , Modelos Animales de Enfermedad , Masculino , Estrés Oxidativo , Ratas , Ratas Sprague-Dawley , Silimarina/uso terapéutico , Ácido Tióctico/uso terapéuticoRESUMEN
Ascorbic acid (AA) accumulation in intestinal epithelial cells is an active transport process mainly mediated by two sodium-dependent vitamin C transporters (SVCT-1 and SVCT-2). To date, little is known about the effect of gut microbiota generated lipopolysaccharide (LPS) on intestinal absorption of water-soluble vitamins. Therefore, the objective of this study was to investigate the effects of bacterially-derived LPS on AA homeostasis in enterocytes using Caco-2 cells, mouse intestine and intestinal enteroids models. Pre-treating Caco-2 cells and mice with LPS led to a significant decrease in carrier-mediated AA uptake. This inhibition was associated with a significant reduction in SVCT-1 and SVCT-2 protein, mRNA, and hnRNA expression. Furthermore, pre-treating enteroids with LPS also led to a marked decrease in SVCT-1 and SVCT-2 protein and mRNA expression. Inhibition of SVCT-1 and SVCT-2 occurred at least in part at the transcriptional level as promoter activity of SLC23A1 and SLC23A2 was attenuated following LPS treatment. Subsequently, we examined the protein and mRNA expression levels of HNF1α and Sp1 transcription factors, which are needed for basal SLC23A1 and SLC23A2 promoter activity, and found that they were significantly decreased in the LPS treated Caco-2 cells and mouse jejunum; this was reflected on level of the observed reduction in the interaction of these transcription factors with their respective promoters in Caco-2 cells treated with LPS. Our findings indicate that LPS inhibits intestinal carrier- mediated AA uptake by down regulating the expression of both vitamin C transporters and transcriptional regulation of SLC23A1 and SLC23A2 genes.
Asunto(s)
Ácido Ascórbico/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Absorción Intestinal/efectos de los fármacos , Intestinos/efectos de los fármacos , Lipopolisacáridos/farmacología , Animales , Ácido Ascórbico/farmacocinética , Transporte Biológico/efectos de los fármacos , Células CACO-2 , Células Cultivadas , Enterocitos/citología , Enterocitos/efectos de los fármacos , Enterocitos/metabolismo , Humanos , Mucosa Intestinal/metabolismo , Intestinos/citología , Masculino , Ratones Endogámicos C57BL , Transportadores de Sodio Acoplados a la Vitamina C/genética , Transportadores de Sodio Acoplados a la Vitamina C/metabolismo , Vitaminas/metabolismo , Vitaminas/farmacocinéticaRESUMEN
In humans, vitamin C (VC) accumulates at higher concentrations in cells than in plasma, and this intracellular accumulation appears critical to several important physiological functions. However, although VC accumulation decreases in the elderly, the influence of cellular senescence on the transport, accumulation, and function of VC is poorly understood. In this study, we investigated the effects of supplementation with both ascorbic acid (AsA) and dehydroascorbic acid (DehAsA) on the uptake and accumulation of VC, AsA, and DehAsA into cells and the effect of AsA on the levels of intracellular reactive oxygen species (ROS) in human fibroblast TIG-1 cells. We also assessed how that supplementation affected senescence-associated changes in intracellular VC transport and accumulation. AsA supplementation significantly increased intracellular levels of AsA, DehAsA, and total VC (i.e., reduced AsA plus oxidized DehAsA) in senescent cells compared with young cells. DehAsA supplementation also significantly increased intracellular AsA and total VC levels in senescent cells, but not DehAsA, and the increases were less than after adding AsA. Among the molecules related to VC accumulation, the mRNA and protein expressions of sodium-dependent VC transporter 2 (SLC23A2) were increased in senescent cells. Furthermore, intracellular peroxide and superoxide anion levels were higher in senescent cells, with AsA supplementation markedly attenuating spontaneous intracellular peroxide accumulation. Overall, our results therefore suggest that VC transport and accumulation improved in senescent human fibroblast TIG-1 cells due to the adaptive upregulation of sodium-dependent VC transporter 2 in response to increased ROS levels. We conclude that adequate supplementation with AsA can effectively mitigate senescence-associated intracellular ROS.
Asunto(s)
Ácido Ascórbico , Senescencia Celular/efectos de los fármacos , Fibroblastos/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Transportadores de Sodio Acoplados a la Vitamina C/metabolismo , Ácido Ascórbico/farmacocinética , Ácido Ascórbico/farmacología , Transporte Biológico Activo/efectos de los fármacos , Línea Celular , Fibroblastos/citología , Humanos , Transportadores de Sodio Acoplados a la Vitamina C/genéticaRESUMEN
Relative to normal cells, tumor cells lack adequate capability of reactive oxygen scavenging. Thus, tumor cells can be selectively killed by increasing the concentration of reactive oxygen species in tumor tissue. In this report, we construct an integrated multifunctional polymeric nanoparticle which can selectively improve hydrogen peroxide (H2O2) levels in tumor tissue and convert them into more active hydroxyl radicals by Fenton reaction. First, the diblock copolymers containing polyethylene glycol (PEG) and poly(glutamic acid) modified by ß-cyclodextrin (ß-CD) were synthesized. The block copolymer, ferrocenecarboxylic acid hexadecyl ester (DFc), and ascorbyl palmitate (PA) were coassembled in aqueous solution to obtain stable core-shell micelles through the inclusion complexation between ß-CD moieties in the block copolymer and ferrocene (Fc) groups from DFc. After intravenous injection, the particles achieved significant accumulation in tumor tissue where ascorbic acid at the pharmacological concentration promotes the production of H2O2, and subsequently Fenton reaction was catalyzed by Fc groups to produce hydroxyl radicals to efficiently kill cancer cells and suppress tumor growth. The micellar systems possess great potentials toward cancer therapy through synergistic H2O2 production and conversion into hydroxyl radicals specifically in tumor tissue.
Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacología , Nanopartículas/química , Polímeros/química , Animales , Ácido Ascórbico/análogos & derivados , Ácido Ascórbico/química , Ácido Ascórbico/farmacocinética , Ácido Ascórbico/farmacología , Femenino , Compuestos Ferrosos/química , Humanos , Peróxido de Hidrógeno/química , Peróxido de Hidrógeno/metabolismo , Radical Hidroxilo/química , Radical Hidroxilo/metabolismo , Inyecciones Intravenosas , Hierro/química , Células MCF-7 , Metalocenos , Ratones Endogámicos BALB C , Micelas , Nanopartículas/administración & dosificación , Polietilenglicoles/química , Ácido Poliglutámico/química , Polímeros/farmacocinética , Polímeros/farmacología , Ensayos Antitumor por Modelo de Xenoinjerto , beta-Ciclodextrinas/químicaRESUMEN
This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2018. Other selected articles can be found online at https://www.biomedcentral.com/collections/annualupdate2018 . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901 .
Asunto(s)
Ácido Ascórbico/farmacocinética , Daño por Reperfusión/tratamiento farmacológico , Factores de Tiempo , Síndrome Coronario Agudo/complicaciones , Síndrome Coronario Agudo/tratamiento farmacológico , Administración Intravenosa , Ácido Ascórbico/uso terapéutico , Deficiencia de Ácido Ascórbico/tratamiento farmacológico , Deficiencia de Ácido Ascórbico/etiología , Humanos , Daño por Reperfusión/fisiopatología , Daño por Reperfusión/prevención & control , Vitaminas/farmacocinética , Vitaminas/uso terapéuticoRESUMEN
This study aimed at the in vitro evaluation of topical hydrogels containing vitamin C-loaded self-double-emulsifying drug delivery system (SDEDDS). The liquid SDEDDS was converted into suitable unmodified xanthan gum hydrogels formulation and the prepared semi-solid hydrogels provided appropriate gel characteristics like pH, viscosity, spreadability, etc. The 5-week storage test displayed that the prepared hydrogels possessed good physicochemical stability. In addition, no significant cytotoxicity to L929 cells was observed for the vitamin C-loaded SDEDDS-based hydrogels, and the prepared hydrogels depicted a sustained drug release over an 8-h period. In vitro permeation study showed that the vitamin C-loaded SDEDDS-based hydrogels could significantly enhance vitamin C retention in the skin and permeation through the skin. The overall results demonstrated that the hydrogels containing vitamin C-loaded SDEDDS could be considered as a promising formulation for topical application.
Asunto(s)
Ácido Ascórbico , Hidrogeles , Absorción Cutánea/efectos de los fármacos , Administración Tópica , Animales , Ácido Ascórbico/química , Ácido Ascórbico/farmacocinética , Ácido Ascórbico/farmacología , Línea Celular , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/farmacocinética , Preparaciones de Acción Retardada/farmacología , Emulsiones , Hidrogeles/química , Hidrogeles/farmacocinética , Hidrogeles/farmacología , Ratones , PorcinosRESUMEN
Vitamin C, as an antioxidant additive in pharmaceutical and food products, is susceptible to environmental conditions, and new design strategies are needed to enhance its stability. The aim of this study is to prepare vitamin C proliposome using film deposition on the carrier by applying different factors, and optimise the characteristics of the obtained powder using the design expert® software. The optimised formulation demonstrated acceptable flowability with 20% vitamin C loading. This formulation released about 90% vitamin C within 2 h and showed higher (1.7-fold) in-vitro antioxidant activity. Ex-vivo antioxidant activity was 1.9 and 1.6 times higher in brain and liver cells, respectively. A 27% reduction in malondialdehyde (MDA) level of liver cell was obtained comparing free vitamin C. Therefore, this study results suggest that the vitamin C-encapsulated proliposome powder might be an appropriate carrier for oral drug delivery of vitamin C with better antioxidant efficacy.
Asunto(s)
Antioxidantes/administración & dosificación , Antioxidantes/farmacología , Ácido Ascórbico/administración & dosificación , Ácido Ascórbico/farmacología , Liposomas/química , Animales , Antioxidantes/farmacocinética , Ácido Ascórbico/farmacocinética , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Diseño de Fármacos , Liberación de Fármacos , Peroxidación de Lípido/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Malondialdehído/metabolismo , Ratas Wistar , Programas Informáticos , SolubilidadRESUMEN
Intravenous administration of high-dose ascorbic acid (AA) has been reported as a treatment for cancer patients. However, cancer patients with renal failure cannot receive this therapy because high-dose AA infusion can have side effects. To solve this problem, we evaluated the antitumor activity of a lipophilic stable AA derivative, 2-O-α-d-glucopyranosyl-6-O-(2-pentylheptanoyl)-l-ascorbic acid (6-bOcta-AA-2G). Intravenous administration of 6-bOcta-AA-2G suppressed tumor growth in colon-26 tumor-bearing mice more strongly than did AA, even at 1/10 of the molar amount of AA. Experiments on the biodistribution and clearance of 6-bOcta-AA-2G and its metabolites in tumor-bearing mice showed that 6-bOcta-AA-2G was hydrolyzed to 6-O-(2-propylpentanoyl)-l-ascorbic acid (6-bOcta-AA) slowly to yield AA, and the results suggested that this characteristic metabolic pattern is responsible for making the antitumor activity of 6-bOcta-AA-2G stronger than that of AA and that the active form of 6-bOcta-AA-2G showing antitumor activity is 6-bOcta-AA. In in vitro experiments, the oxidized form of 6-bOcta-AA as well as 6-bOcta-AA showed significant cytotoxicity, while the oxidized forms of ascorbic acid showed no cytotoxicity at all, suggesting that the antitumor activity mechanism of 6-bOcta-AA-2G is different from that of AA and that the antitumor activity is due to the reduced and oxidized form of 6-bOcta-AA. The findings suggest that 6-bOcta-AA-2G is a potent candidate as an alternative drug to intravenous high-dose AA.
Asunto(s)
Antineoplásicos/uso terapéutico , Ácido Ascórbico/análogos & derivados , Ácido Ascórbico/uso terapéutico , Glucósidos/uso terapéutico , Neoplasias Experimentales/tratamiento farmacológico , Animales , Antineoplásicos/síntesis química , Antineoplásicos/farmacocinética , Ácido Ascórbico/síntesis química , Ácido Ascórbico/farmacocinética , Línea Celular Tumoral , Femenino , Glucósidos/síntesis química , Glucósidos/farmacocinética , Ratones , Ratones Endogámicos BALB C , Distribución TisularRESUMEN
The anticancer potential of ascorbic acid (AA) has been controversially discussed for decades. Although the cytotoxic effect of pharmacologic concentrations of ascorbic acid has already been successfully demonstrated in numerous studies in vitro, it could not be verified to the same extent in vivo. We propose that the ubiquitous metabolite pyruvate diminishes the effect of AA by reacting with its presumable cytotoxic mediator hydrogen peroxide (H2O2). MTT assays confirm that co-incubation with 1.4 mM pyruvate abolishes the cytotoxic effect of pharmacologic concentrations of AA in all cancer cell lines tested (human melanoma (WM451-Lu), breast (MCF-7) and hypopharyngeal cancer cells (FaDu)). We further investigated whether pyruvate diminishes the anticancer effect of AA by interfering with the generation of H2O2. Therefore, we analyzed the concentration of AFR, a proposed intermediate in the AA-dependent formation of H2O2, by electron paramagnetic resonance spectroscopy, during incubation with AA and pyruvate in WM451-Lu cells as a model system. In addition, we measured H2O2 concentration by indirect detection with Clark-type oxygen electrode. AFR concentration was not significantly influenced by pyruvate, whereas H2O2 concentration was significantly reduced. In parallel, pyruvate concentrations of the stimulation medium declined with increasing AA and consequently H2O2 concentrations. In summary, pyruvate diminishes the cytotoxic activity of ascorbic acid in vitro. The AFR concentration measured remains unaffected by pyruvate whereas the H2O2 concentration is reduced; confirming that pyruvate directly reacts with AA-induced H2O2, without influencing its formation. However, further experiments are needed to elucidate the complex mechanisms being responsible for the reduced efficacy of AA in vivo.